Open Access

Rivaroxaban treatment for young patients with pulmonary embolism (Review)

  • Authors:
    • Haidi Wu
    • Hongyan Cao
    • Zikai Song
    • Xiaoyan Xu
    • Minglong Tang
    • Shuo Yang
    • Yang Liu
    • Ling Qin
  • View Affiliations

  • Published online on: May 25, 2020     https://doi.org/10.3892/etm.2020.8791
  • Pages: 694-704
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pulmonary embolism (PE) is a serious, life‑threatening condition that affects young populations (>18 and <50 years old, according to most literature reviews) with improved recognition of its clinical manifestations and the widespread use of sensitive imaging techniques, PE is increasingly diagnosed in younger patients. At present, there is limited understanding of the clinical features and adequate anticoagulant treatment options for this population. Most studies to date have yet to demonstrate significant differences in PE pathophysiology or symptoms between young and elderly patients. Although the overall incidence of PE is lower in young populations compared with elderly patients, important risk factors also apply for young patients. Hereditary thrombophilia is common and is a major cause of PE in younger patients. Immobilization, trauma, obesity, smoking and infection are also becoming increasingly frequent in young patients with PE. Among female patients, oral contraceptive use, pregnancy and postpartum status are predominant risk factors underlying PE. Rivaroxaban is a direct oral anticoagulant with a rapid onset of action that is associated with less drug‑drug interactions compared with other therapies. Because the drug is administered at fixed doses with no requirement for routine coagulation monitoring, it is becoming an attractive option for anticoagulation treatment in young patients with PE. Therefore, the present literature review focuses on the clinical characteristics of PE and rivaroxaban therapy in younger patients.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu H, Cao H, Song Z, Xu X, Tang M, Yang S, Liu Y and Qin L: Rivaroxaban treatment for young patients with pulmonary embolism (Review). Exp Ther Med 20: 694-704, 2020
APA
Wu, H., Cao, H., Song, Z., Xu, X., Tang, M., Yang, S. ... Qin, L. (2020). Rivaroxaban treatment for young patients with pulmonary embolism (Review). Experimental and Therapeutic Medicine, 20, 694-704. https://doi.org/10.3892/etm.2020.8791
MLA
Wu, H., Cao, H., Song, Z., Xu, X., Tang, M., Yang, S., Liu, Y., Qin, L."Rivaroxaban treatment for young patients with pulmonary embolism (Review)". Experimental and Therapeutic Medicine 20.2 (2020): 694-704.
Chicago
Wu, H., Cao, H., Song, Z., Xu, X., Tang, M., Yang, S., Liu, Y., Qin, L."Rivaroxaban treatment for young patients with pulmonary embolism (Review)". Experimental and Therapeutic Medicine 20, no. 2 (2020): 694-704. https://doi.org/10.3892/etm.2020.8791